Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression

Neurobiology of Disease

Volumn 55, Issue , 2013, Pages 37-43

  Leoni, Valerio ^a   Long, Jeffrey D ^b   Mills, James A ^b   Di Donato, Stefano ^a   Paulsen, Jane S ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Biomarkers; Cholesterol; Huntington disease; Neurodegenerative disease

Indexed keywords

24 HYDROXYCHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAG REPEAT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE MARKER; FEMALE; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; NERVE CELL DEGENERATION; PHENOTYPIC VARIATION; PRIORITY JOURNAL; WHITE MATTER;

ADULT; COGNITION DISORDERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HUNTINGTON DISEASE; HYDROXYCHOLESTEROLS; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; STATISTICS AS TOPIC; VERBAL LEARNING;

EID: 84876731616     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.03.013     Document Type: Article

References (56)

1. Akaike H. Information theory as an extension of the maximum likelihood principle. Second International Symposium on Information Theory 1973, Akademiai Kiado.
2. Aylward E.H. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res. Bull. 2007, 72:152-158.
3. Aylward E.H., Sparks B.F., Field K.M., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
4. Bates D., Maechler M., Bolker B. lme4: linear mixed-effects models using S4 classes, 2011 (R package version 0999375-42). http://cran.r-project.org/package/=lme4.
5. Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 2006, 260:493-508.
6. Björkhem I., Cedazo-Minguez A., Leoni V., Meaney S. Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 2009, 30(3):171-179. (Jun).
7. Brandt J., Benedict R.H.B. Hopkins Verbal Learning Test - Revised: Professional Manual 1991, Psychological Assessment Resources, Lutz, FL.
8. Bretillon L., Lutjohann D., Stahle L., Widhe T., Bindl L., Eggersten G., Diczfalusy U., Bjorkhem I. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J. Lipid Res. 2000, 41:840-845.
9. Burnham K.P., Anderson D.R. Model selection and multi-model inference: a practical information-theoretic approach 2002, Springer.
10. Crainiceanu C., Ruppert D. Likelihood ratio tests in linear mixed models with one variance component. J. R. Stat. Soc. Ser. B 2004, 66:165-185.
11. Dietschy J.M., Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45:1375-1397.
12. Doty R.L., Shaman P., Kimmelman C.P., Dann M.S. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984, 94(2 Pt 1):176-178. (Feb).
13. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122:1667-1678.
14. Henley S.M., Wild E.J., Hobbs N.Z., Frost C., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov. Disord. 2009, 24:932-936.
15. Hobbs N., Barnes J., Frost C., et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am. J. Neuroradiol. 2010, 31(6):1036-1041.
16. Hothorn T., Bretz F., Westfall P. Simultaneous inference in general parametric models. Biom. J. 2008, 50(3):346-363.
17. Katsuno M., Adachi H., Sobue G. Getting a handle on Huntington's disease: the case for cholesterol. Nat. Med. 2009, 15(3):253-254. (Mar).
18. Kolsch H., Heun R., Kerksiek A., Bergmann K.V., Maier W., Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 2004, 368:303-308.
19. Langbehn D.R., Hayden M.R., Paulsen J.S., Group P-HIotHS CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B(2):397-408. (Mar 5).
20. Leoni V., Caccia C. 24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie 2012, 95:595-612.
21. Leoni V., Masterman T., Diczfalusy U., De Luca G., Hillert J., Björkhem I. Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci. Lett. 2002, 331:163-166.
22. Leoni V., Mariotti C., Tabrizi S.J., Valenza M., Wild E.J., Henley S.M., Hobbs N.Z., Mandelli M.L., Grisoli M., Björkhem I., Cattaneo E., Di Donato S. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008, 131:2851-2859.
23. Leoni V., Mariotti C., Nanetti L., Salvatore E., Squitieri F., Bentivoglio A.R., Bandettini Del Poggio M., Piacentini S., Monza D., Valenza M., Cattaneo E., Di Donato S. Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci. Lett. 2011, 494(3):245-249. (May 2).
24. Localio A.R., Berlin J.A., Have T.R.T. Confounding due to cluster in multicenter studies - causes and cures. Health Serv. Outcomes Res. Methodol. 2002, 3(3):195-210.
25. Long J.D. Longitudinal Data Analysis for the Behavioral Sciences Using R 2012, Sage Publications Inc.
26. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U. S. A. 1999, 6:7238-7243.
27. Lund E.G., Xie C., Kotti T., Turley S.D., Dietschy J.M., Russell D.W. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 2003, 278(25):22980-22988. (Jun 20, Epub 2003 Apr 9. PubMed PMID: 12686551).
28. Lütjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden Å., Diczfalusy U., et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9799-9804.
29. Magnotta V.A., Harris G., Andreasen N.C., O'Leary D.S., Yuh W.T., Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput. Med. Imaging Graph. 2002, 26:251-264.
30. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am. J. Psychiatry 2007, 164(9):1428-1434. (Sep).
31. Nopoulos P.C., Aylward E.H., Ross C.A., et al. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 2011, 134(Pt. 1):137-142. (Jan).
32. Papassotiropoulos A., Lütjohann D., Bagli M., Locatelli S., Jessen F., Rao M.L., Maier W., Björkhem I., von Bergmann K., Heun R. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000, 11:1959-1962.
33. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M., Predict-HD Investigators and Coordinators of the Huntington Study Group Detection of Huntington's disease decades before diagnosis, the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
34. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 1997, 41(5):689-692. (May).
35. Pierson R.K., Johnson H.J., Harris G., Keefe H., Paulsen J., Andreasen N.C., Magnotta V.A. Fully automated analysis using BRAINS: AutoWorkup. Neuroimage 2011, 54(1):328-336. (Jan 1).
36. Pinheiro J.C., Bates D.M. Mixed-effects Models in S and S-PLUS 2000, Springer Verlag.
37. R Core Team R: A Language and Environment For Statistical Computing 2013, R Foundation for Statistical Computing, Vienna, Austria, (URL http://www.R-project.org/).
38. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10(1):83-98. (Jan, Review. PubMed PMID: 21163446).
39. Rowe K.C., Paulsen J.S., Langbehn D.R., et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010, 24(4):435-442. (Jul).
40. Shobab L.A., Hsiung G.Y., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4:841-852.
41. Smith A. Symbol Digit Modalities Test (SDMT). Manual (revised) 1982, Western Psychological Services, Los Angeles.
42. Solomon A., Leoni V., Kivipelto M., Besga A., Oksengård A.R., Julin P., Svensson L., Wahlund L.O., Andreasen N., Winblad B., Soininen H., Björkhem I. Plasma levels of 24-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 2009, 462:89-93.
43. Stroop J.R. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 28:643-662.
44. The Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 1996, 11(2):136-142. (Mar).
45. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72(6):971-983. (Mar 26).
46. Thelen K.M., Lütjohann D., Vesalainen R., Janatuinen T., Knuuti J., von Bergmann K., Lehtimäki T., Laaksonen R. Effect of pravastatin on plasma sterols and oxysterols in men. Eur. J. Clin. Pharmacol. 2006, 62(1):9-14. (Jan).
47. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., Mariotti C., Di Donato S., Corsini A., Bates G., Pruss R., Olson J.M., Sipione S., Tartari M., Cattaneo E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 2005, 25:9932-9939.
48. Valenza M., Leoni V., Tarditi A., Mariotti C., Bjorkhem I., Di Donato S., Cattaneo E. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2007, 28:133-142.
49. Valenza M., Leoni V., Karasinska J.M., Petricca L., Fan J., Carroll J., Pouladi M.A., Fossale E., Nguyen H.P., Riess O., MacDonald M., Wellington C., DiDonato S., Hayden M., Cattaneo E. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J. Neurosci. 2010, 30:10844-10850.
50. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57(5):369-384. (May, Review. PubMed PMID: 9596408).
51. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
52. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
53. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
54. Weir D.W., Sturrock A., Leavitt B.R. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011, 10(6):573-590. (Jun, Review. PubMed PMID: 21601164).
55. Zhang Y., Long J.D., Mills J.A., Warner J.H., Lu W., Paulsen J.S., PREDICT-HD Investigators Coordinators of the Huntington Study Group Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B(7):751-763. (Dec).
56. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoff mann R.G., Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J. Int. Neuropsychol. Soc. 2007, 13:758-769.